(marketscreener.com) By Colin Kellaher Shares of F-star Therapeutics Inc. jumped more than 15% after U.S. regulators finally approved the acquisition of the clinical-stage biopharmaceutical company by a unit of Sino Biopharmaceutical Ltd. F-star last year agreed to be acquired by Sino's invoX unit for about $161 million, or $7.12 a share, but the U.S....https://www.marketscreener.com/quote/stock/F-STAR-THERAPEUTICS-INC-115594552/news/F-star-Therapeutics-Shares-Rally-After-Cfius-Clears-Takeover-43182352/?utm_medium=RSS&utm_content=20230307
F-star is an England-based biotechnology company that develops and commercializes novel antibody therapies for the treatment of cancer and orphan diseases.